Crossmark

Restoring Protein Expression in Neuromuscular Conditions: A Review Assessing the Current State of Exon Skipping/Inclusion and Gene Therapies for Duchenne Muscular Dystrophy and Spinal Muscular Atrophy

Crossref DOI link: https://doi.org/10.1007/s40259-021-00486-7

Published Online: 2021-06-07

Published Print: 2021-07

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Sheikh, Omar

Yokota, Toshifumi https://orcid.org/0000-0003-1291-497X
Funding

Funding for this research was provided by:

WCHRI
License Information

Text and Data Mining valid from 2021-06-07

Version of Record valid from 2021-06-07
More Information

Article History

Accepted: 14 May 2021

First Online: 7 June 2021

Declarations

:

: TY is a founder and shareholder of OligomicsTx, which aims to commercialize antisense oligonucleotide technology. OS has no conflicts of interest to report.

: Literature review draft preparation by Omar Sheikh. Supervision and funding acquisition by Toshifumi Yokota. Review and editing performed jointly. All authors have read and agreed to the published version of the manuscript.

: This work was supported by Muscular Dystrophy Canada, the Friends of Garrett Cumming Research Fund, the HM Toupin Neurological Science Research Fund, Fulbright Scholarship Program, and the Women and Children’s Health Research Institute (WCHRI).

: Not applicable.

: Not applicable.

: Not applicable.

: Not applicable.

: Not applicable.

: The authors wish to thank Mary Claire De Villa for writing feedback.

Document is current

Any future updates will be listed below